Poxel snags Janssen exec to head new Japanese subsidiary

13 September 2018

Based on its strong focus on the Asian market, French metabolic diseases biotech company Poxel (Euronext: POXEL) has made another significant move to solidify its position, forming a fully-owned Japanese subsidiary, Poxel KK.

In addition, Poxel has appointed Takashi Kaneko as senior vice president medical and president of Poxel Japan KK effective September 1, 2018, to lead the company’s drug development and medical affairs activities as well as the team in Japan.

Dr Kaneko joins Poxel from Janssen Pharmaceutical KK, part of the Johnson & Johnson (NYSE: JNJJ) group, where he was head of medical affairs with over 33 years of pharmaceutical industry experience and a focus on medical affairs and clinical development up to commercial launch. Prior to Janssen Pharmaceutical KK, he was the department head of the medical excellence department in the Medical Division at Novartis KK.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK